natgillin/translations-raw huggingface dataset:
In a subset of subjects, body composition was measured using dual energy X-ray absorptiometry (DEXA) (naltrexone / bupropion = 79 subjects and placebo = 45 subjects) and multislice computed tomography (CT) scan (naltrexone / bupropion = 34 subjects and placebo = 24 subjects).
U podskupini ispitanika, sastav tijela je mjeren koristeći dvoenergetsku rendgensku apsorpciometriju (engl. dual energy X ray absorptiometry, DEXA) (naltrekson / bupropion = 79 ispitanika i placebo = 45 ispitanika) i oslikavanjem višeslojnom kompjuteriziranom tomografijom (engl. computed tomography, CT), (naltrekson / bupropion = 34 ispitanika i placebo = 24 ispitanika).
In a subset of young adult SJIA patients aged 16 to 20 years (n=31), the safety profile of Ilaris was consistent with what was observed in SJIA patients less than 16 years of age.
U podskupini mladih bolesnika sa SJIA-om u dobi od 16 do 20 godina (n=31), sigurnosni profil Ilarisa bio je u skladu s onim što je zabilježeno u bolesnika sa SJIA-om mlađih od 16 godina.
In a substudy, a small group of patients who had previously received either tetanus, pneumococcal or influenza vaccinations were found to maintain protective titres after treatment with Benlysta.
U jednoj se podstudiji pokazalo da je mala skupina bolesnika koji su prethodno primili cjepivo protiv tetanusa, pneumokoka ili gripe zadržala zaštitne titre nakon liječenja lijekom Benlysta.
In a supplemental analysis, the efficacy of Silgard was evaluated against HPV 16/18-related CIN 3 and AIS.
U dopunskoj analizi ocijenjena je djelotvornost cjepiva Silgard protiv CIN-a 3 i AIS-a povezanih s HPV tipovima 16 i 18.
In a supporting study of ReFacto AF, 1 de novo and 2 recurrent inhibitors (all low-titre, central laboratory determination) were observed in 110 patients; median exposure of 58 ED (range 5-140) and 98 patients had at least 50 ED to ReFacto AF.
U potpornom ispitivanju lijeka ReFacto AF, 1 de novo i 2 ponovne pojave inhibitora (svi u niskom titru, određeni u središnjem laboratoriju) bile su opažene u 110 bolesnika; medijan izloženosti bio je 58 ED (raspon 5-140) i 98 bolesnika imalo je najmanje 50 ED za ReFacto AF.
In a supporting study, patients who were being treated with effective HIV treatment either continued with the same treatment or were switched to Genvoya.
U studiji potpore bolesnici liječeni učinkovitom terapijom protiv HIV-a nastavili su s istom terapijom ili su prebačeni na lijek Genvoya.
In a surveillance study conducted by the US CDC (Griffin, et al, 2011) the effectiveness of the H1N1 pandemic LAIV vaccine in children 2 through 9 years of age was estimated at 81.9% (95% CI:13.6, 96.2).
U nadzornom ispitivanju koje je proveo Američki centar za kontrolu bolesti (Griffin, et al, 2011), procijenjeno je da djelotvornost pandemijskog H1N1 LAIV cjepiva u djece u dobi od 2 do 9 godina iznosi 81,9% (95% CI:13,6, 96,2).
In a surveillance study in France in children presenting with acute otitis media, changes in nasopharyngeal (NP) carriage of pneumococcal serotypes were evaluated following the introduction of Prevenar (7-valent) and subsequently Prevenar 13.
Kod djece sa simptomima akutne upale srednjeg uha u preglednoj studiji u Francuskoj procjenjivale su se promjene nazofaringalnog kliconoštva pneumokoknih serotipova nakon uvođenja Prevenara (7- valentnog) i nastavno Prevenara 13.
In a taste preference study in adults, SUSTIVA mixed with grape jelly received the best rating.
U ispitivanju preferencije okusa u odraslih, SUSTIVA pomiješana sa želeom od grožđa dobila je najviše ocjene.
In a third clinical trial (Study V87P11) 194 adult subjects were enrolled and received two doses of vaccine containing H5N1 (A/H5N1/turkey/Turkey/1/05; 7.5 µg HA/dose adjuvanted) administered three weeks apart.
U treće kliničko ispitivanje (Studija V87P11) uključene su 194 odrasle osobe koje su primile dvije doze cjepiva koje sadrži virus H5N1 (A/H5N1/turkey/Turkey/1/05; 7,5 µg HA/dozi adjuvantirano) u razmaku od tri tjedna.
In a third phase III randomised, double-blind trial, 4 mg zoledronic acid or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion.
U randomiziranom, dvostruko slijepom ispitivanju faze III uspoređivala se zoledronatna kiselina u dozi od 4 mg s pamidronatom u dozi od 90 mg svaka 3 do 4 tjedna u bolesnika s multiplim mijelomom ili karcinomom dojke i najmanje jednom koštanom lezijom.
In a third phase III randomised, double-blind trial, zoledronic acid 4 mg or 90 mg pamidronate every 3 to 4 weeks were compared in patients with multiple myeloma or breast cancer with at least one bone lesion.
U randomiziranom, dvostruko slijepom ispitivanju faze III uspoređivala se zoledronatna kiselina u dozi od 4 mg s pamidronatom u dozi od 90 mg svaka 3 do 4 tjedna u bolesnika s multiplim mijelomom ili rakomrakom dojke i najmanje jednom koštanom lezijom.
In a third randomised, double-blind clinical trial, enrolling 87 patients, Ameluz and placebo were compared on entire treatment fields (field cancerization) containing 4 to 8 AK lesions in a field area of maximum 20 cm2.
U trećem randomiziranom, dvostruko slijepom kliničkom ispitivanju koje je uključilo 87 bolesnika, Ameluz i placebo bili su uspoređeni na svim liječenim područjima (područjima zloćudne transformacije) na kojima je bilo 4 do 8 lezija aktiničke keratoze na površini veličine maksimalno 20 cm2.
In a third study in adults aged 50-93 years, it was demonstrated that Prevenar 13 may be given concomitantly with the seasonal quadrivalent inactivated influenza vaccine (QIV).
U trećem ispitivanju u odraslih u dobi od 50 do 93 godine dokazano je da se Prevenar 13 može davati istovremeno sa sezonskim četverovalentnim inaktiviranim cjepivom protiv gripe.
In a third study, 254 pigs infected with Trichuris suis were treated either with Panacur AquaSol or received no treatment.
U trećem ispitivanju 254 svinje zaražene s Trichuris suis liječene su VMP-om Panacur AquaSol ili nisu uopće liječene.
In a third trial, Myocet (75 mg/m2) monotherapy was compared with conventional doxorubicin monotherapy (at the same dose).
U trećem ispitivanju, monoterapija Myocetom (75 mg/m2) bila je uspoređena sa standardnom monoterapijom doksorubicinom (pri istoj dozi).
In a thorough QT study, rufinamide produced a decrease in QTc interval proportional to concentration.
U temeljitom ispitivanju učinaka na QT interval, rufinamid je izazvao skraćenje QTc intervala, koje je bilo proporcionalno koncentraciji.
In a thorough QTc study in 60 healthy subjects, there was no effect of therapeutic doses of Erivedge on the QTc interval.
U temeljitom ispitivanju QTc-intervala u 60 zdravih ispitanika nije primijećen učinak terapijskih doza lijeka Erivedge na QTc-interval.
In a three-month, controlled clinical study in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 27 to 30 mmHg, the mean IOP-lowering effect of DuoTrav dosed once-daily in the morning was 9 to 12 mmHg, and was up to 2 mmHg greater than that of travoprost 40 micrograms/ml dosed once-daily in the evening and 2 to 3 mmHg greater than that of timolol 5 mg/ml dosed twice daily.
U tromjesečnoj, kontroliranoj kliničkoj studiji u bolesnika s glaukomom otvorenog kuta ili hipertenzijom oka i prosječnim početnim IOT od 27 do 30 mmHg prosječni učinak sniženja IOT DuoTrav kapi doziranih jednom dnevno ujutro bio je 9 do 12 mmHg, i bio je do 2 mmHg veći nego onaj travoprosta 40 mikrograma/ml doziranog jednom dnevno navečer i 2 do 3 mmHg veći nego učinak timolola 5 mg/ml doziranog dvaput dnevno.
In a topical ocular study, at steady-state, brinzolamide RBC concentrations were similar to those found in the oral study, but levels of N-desethylbrinzolamide were lower.
U ispitivanju lokalne primjene u oko, u stanju dinamičke ravnoteže, koncentracija brinzolamida u eritrocitima bila je slična vrijednosti dobivenoj u oralnoj studiji, ali je koncentracija N-desetil- brinzolamida bila niža.
In a total of four clinical trials, approximately 3800 doses of Rotarix liquid formulation were administered to approximately 1900 infants.
U ukupno četiri klinička ispitivanja, primijenjeno je oko 3800 doza tekuće formulacije cjepiva Rotarix u oko 1900 dojenčadi.
In a total of twenty-three clinical trials, approximately 106000 doses of Rotarix (lyophilised or liquid formulation) were administered to approximately 51000 infants.
U ukupno dvadeset i tri klinička ispitivanja primijenjeno je oko 106 000 doza cjepiva Rotarix (liofilizirane ili tekuće formulacije) u oko 51 000 dojenčadi.
In a treatment cycle, Dacogen is administered at a dose of 20 mg/m2 body surface area by intravenous infusion over 1 hour repeated daily for 5 consecutive days (i.e., a total of 5 doses per treatment cycle).
U jednom ciklusu liječenja, Dacogen se primjenjuje u dozi od 20 mg/m2 tjelesne površine intravenskom infuzijom u trajanju od 1 sata, doza se ponavlja svaki dan tijekom 5 uzastopnih dana (tj. ukupno 5 doza u jednom ciklusu liječenja).
In a trial with 14C, Aivlosin administered at 2.125 mg/kg to pigs for 7 days over 70% of the dose was excreted in the faeces, with urinary excretion accounting for 3 to 4% of the dose.
U ispitivanju u kojem je 14C Aivlosin u dozi od 2,125 mg/kg primjenjivan svinjama u trajanju od 7 dana, više od 70% doze bilo je izlučeno u stolici dok je 3 do 4 % doze bilo izlučeno mokraćom.
In a twelve-month, controlled clinical study in patients with open-angle glaucoma or ocular hypertension and baseline mean IOP of 25 to 27 mmHg, the mean IOP-lowering effect of DuoTrav dosed once-daily in the morning was 8 to 10 mmHg.
U dvanaestomjesečnoj, kontroliranoj kliničkoj studiji u bolesnika s glaukomom otvorenog kuta ili hipertenzijom oka i prosječnom početnom vrijednosti IOT od 25 do 27 mmHg, prosječni učinak sniženja IOT DuoTrav kapi doziranih jednom dnevno ujutro bio je 8 do 10 mmHg.
In a twelve-month, controlled clinical trial in patients with open-angle glaucoma or ocular hypertension who, in the investigator’s opinion could benefit from a combination therapy, and who had baseline mean IOP of 25 to 27 mmHg, the mean IOP-lowering effect of AZARGA dosed twice daily was 7 to 9 mmHg.
U 12-mjesečnom kontroliranom kliničkom istraživanju u bolesnika s glaukomom otvorenog kuta ili s očnom hipertenzijom koji su, prema ocjeni ispitivača, mogli imati koristi od kombiniranog liječenja, i u kojih je srednji očni tlak prije početka liječenja bio 25 do 27 mmHg, primjenom AZARGE dvaput na dan srednji se očni tlak snizio za 7 do 9 mmHg.
In a two-arm study, 329 adult patients with AK on the face or scalp were randomised to treatment with Picato gel, 150 mcg/g or vehicle 3 weeks after cryotherapy of all visible lesions in the treatment area.
U ispitivanju s dvije skupine bolesnika, 329 odraslih bolesnika s aktiničkom keratozom na licu ili vlasištu bilo je randomizirano za liječenje lijekom Picato gel, 150 µg/g ili podlogom 3 tjedna nakon krioterapije svih vidljivih lezija na liječenom području.
In a UK study, the functional antibody (OPA) responses were comparable for all serotypes including 6B and 23F in the Prevenar and Prevenar 13 arms after the primary series at two and four months of age and after the booster dose at 12 months of age.
U ispitivanju provedenom u Velikoj Britaniji, odgovor funkcionalnih protutijela (OPA) u skupinama koje su primile Prevenar i Prevenar 13 bio je usporediv za sve serotipove, uključujući 6B i 23F, nakon serije primarnog cijepljenja u drugom i četvrtom mjesecu života i nakon docjepljivanja u 12. mjesecu života.
In about 20% of these cases there were no risk factors for acute renal failure such as concomitant nephrotocix medical products and gastro- intestinal disorders.
U otprilike 20% ovih slučajeva nije bilo faktora rizika za akutno zatajenje bubrega, kao što su istodobno primijenjeni nefrotoksični lijek i poremećaji probavnog sustava.
In about 20% of these cases there were no risk factors for acute renal failure such as concomitant nephrotoxic medicinal products and gastro- intestinal disorders.
U otprilike 20% ovih slučajeva nije bilo faktora rizika za akutno zatajenje bubrega, kao što su istodobno primijenjeni nefrotoksični lijek i poremećaji probavnog sustava.
In Abraxane, unlike conventional paclitaxel-containing medicines, the paclitaxel is attached to a human protein called albumin in tiny particles known as ‘nanoparticles’.
Za razliku od konvencionalnih lijekova koji sadrže paklitaksel, u Abraxaneu se paklitaksel veže na ljudsku bjelančevinu naziva albumin u sitnim česticama koje se zovu nanočestice.
In absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Zbog nedostatka ispitivanja kompatibilnosti ovaj lijek se ne smije miješati s drugim lijekovima.
In absence of compatibility studies, this product must not be mixed with other veterinary medicinal products.
U nedostatku ispitivanja kompatibilnosti ovaj veterinarsko-medicinski proizvod se ne smije miješati s drugim veterinarsko-medicinskim proizvodima.
In absence of haemodialysis in patients with endstage renal disease, the levels were increased and continuously rising during the 24-hour sampling.
Kod nehemodijaliziranih bolesnika sa završnim stadijem bubrežne bolesti razine su bile povećane i kontinuirano su rasle tijekom 24-satnog uzorkovanja.
In accordance with Article 114 Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
Sukladno članku 114 Direktive 2001/83/EC, službeno puštanje serije lijeka u promet preuzet će državni laboratoriji ili laboratorij određen za tu svrhu.
In accordance with Article 114 of Directive 2001/83/EC as amended, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose
Sukladno članku 114 Direktive 2001/83/EC te izmjenama i dopunama, službeno puštanje serije lijeka u promet preuzet će državni laboratorij ili laboratorij određen za tu svrhu.
In accordance with Article 114 of Directive 2001/83/EC as amended, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.‌
Sukladno članku 114 Direktive 2001/83/EC, službeno puštanje serije lijeka u promet preuzet će državni laboratoriji ili laboratorij određen za tu svrhu.
In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be taken by a state laboratory or a laboratory designated for that purpose
Sukladno članku 114 Direktive 2001/83/EC službeno puštanje serije lijeka u promet preuzet će državni laboratoriji ili laboratorij određen za tu svrhu.
In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be taken by a state laboratory or a laboratory designated for that purpose.
Sukladno članku 114 Direktive 2001/83/EC, službeno puštanje serije lijeka u promet preuzet će državni laboratorij ili laboratorij određen za tu svrhu.
In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
Sukladno članku 114 Direktive 2001/83/EC, službeno puštanje serije lijeka u promet preuzet će državni laboratorij ili laboratorij određen za tu svrhu.
In accordance with current clinical practice, if lacosamide has to be discontinued, it is recommended this be done gradually (e.g. taper the daily dose by 200 mg/week).
Sukladno trenutačnoj kliničkoj praksi, ako treba prekinuti primjenu lakozamida, preporučeno je postupno ukidanje lijeka (npr. smanjivati dnevnu dozu za 200 mg/tjedan).
In accordance with current clinical practice, if lacosamide has to be discontinued, it is recommended this be done gradually (e.g. taper the daily dose by 200 mg/week).
Sukladno trenutačnoj kliničkoj praksi, ako treba prekinuti primjenu lijeka Vimpat, preporučeno je postupno ukidanje lijeka (npr. smanjivati dnevnu dozu za 200 mg/tjedan).
In accordance with current clinical practice, if pregabalin has to be discontinued it is recommended this should be done gradually over a minimum of 1 week independent of the indication (see sections .4 and 4.8).
Sukladno postojećoj kliničkoj praksi, ako se liječenje pregabalinom mora prekinuti, preporučuje se ukidati ga postupno tijekom najmanje tjedan dana, bez obzira na indikaciju (vidjeti dijelove 4.4 i 4.8).
In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medicinal products.
Sukladno postojećoj kliničkoj praksi, nekim bolesnicima sa šećernom bolešću koji dobivaju na težini tijekom liječenja pregabalinom možda će biti potrebno prilagoditi terapiju antidijabeticima.
In accordance with good animal husbandry, the cleaning and disinfection of the infected birds’ environment with an appropriate antifungal product is recommended.
U skladu s praksama dobrog gospodarenja životinjama treba preporučiti čišćenje i dezinfekciju inficiranog okoliša ptica odgovarajućim antimikoticima.
In accordance with good animal husbandry, the cleaning and disinfection of the infected birds’ environment with an appropriate antifungal product should be recommended.
U skladu s praksama dobrog gospodarenja životinjama treba preporučiti čišćenje i dezinfekciju inficiranog okoliša ptica odgovarajućim antimikoticima.
In accordance with standard medical practice for hepatitis B vaccine administration, regular antibody testing should be done in hemodialysis patients.
U skladu sa standardnom medicinskom praksom primjene cjepiva protiv hepatitisa B, u bolesnika na hemodijalizi potrebno je redovito određivati protutijela.
In acromegaly patients who developed hyperglycaemia, the condition generally appeared to respond to antidiabetic therapy.
U bolesnika s akromegalijom u kojih se razvila hiperglikemija, čini se da je stanje općenito odgovaralo na antidijabetičku terapiju.
In acromegaly, the tumour causes excess production of growth hormone (GH), which stimulates the production of too much IGF-1 (insulin growth factor 1).
U slučaju akromegalije, tumor uzrokuje prekomjerno lučenje hormona rasta (HR), koji zatim stimulira stvaranje prevelike količine IGF-1 (inzulinu sličnog faktora rasta 1).
In acromegaly, this overproduction causes overgrowth of bone, swelling of soft tissue (such as the hands and feet), heart disease and other disorders.
U slučaju akromegalije prekomjerno lučenje uzrokuje prekomjeran rast kostiju, oticanje mekog tkiva (poput ruku i stopala), bolesti srca i druge poremećaje.
In ACTG 245, a double-blind placebo controlled study, the frequency of serious medicinal product-related granulocytopenia was 5/305 (1.6 %).
U ACTG-u 245, dvostruko-slijepom, placebom kontroliranom ispitivanju, učestalost teške granulocitopenije povezane s lijekom bila je 5/305 (1,6%).
In active comparator-controlled trials, mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year.
U ispitivanjima kontroliranima aktivnim usporednim lijekom, srednja vrijednost povećanja težine tijekom monoterapije pioglitazonom bila je 2–3 kg tijekom jedne godine.
In active-controlled gouty arthritis trials, there was a mean increase in triglycerides of 33.5 mg/dl in Ilaris-treated patients compared with a modest decrease of -3.1 mg/dl with triamcinolone acetonide.
U aktivno kontroliranim ispitivanjima uričnog artritisa došlo je do srednjeg povišenja triglicerida od 33,5mg/dl kod bolesnika liječenih Ilarisom, u usporedbi sa skromnim smanjenjem od -3,1 mg/dl s triamcinolon acetonidom.
In acute coronary syndrome and atrial fibrillation, Clopidogrel ratiopharm is used together with aspirin, the dose of which should not be higher than 100 mg.
U slučaju akutnog koronarnog sindroma i arterijske fibrilacije, Clopidogrel rationpharm koristi se zajedno s aspirinom, dozom koja ne smije biti viša od 100 mg.
In acute toxicity studies in rats and monkeys non-specific toxic symptoms such as hypotension and bradycardia were only observed after intravenous administration of ganirelix over 1 and 3 mg/kg, respectively.
U istraživanjima akutne toksičnosti na štakorima i majmunima, nespecifični simptomi toksičnosti poput hipotenzije i bradikardije opaženi su samo nakon intravenske primjene ganireliksa u dozama većim od 1 mg/kg odnosno 3 mg/kg.
In acute toxicity studies in rodents non-specific toxic symptoms were observed after intraperitoneal administration of cetrorelix doses more than 200 times higher than the pharmacologically effective dose after subcutaneous administration.
U istraživanjima o akutnoj toksičnosti u glodavaca, primijećeni su nespecifični simptomi toksičnosti nakon intraperitonealne primjene doza cetrotreliksa većih od 200 puta od farmakološki aktivne doze nakon supkutane primjene.
In AD patients, cortical regions and striatal regions show significantly greater uptake compared to cortical regions in controls.
U bolesnika s AB- om, kortikalna i strijatalna područja pokazuju značajno veće nakupljanje u usporedbi s kortikalnim područjima zdravih kontrolnih ispitanika.
In AD subjects, as in controls, there is low retention in cerebellum and hippocampus and high retention in pons and centrum semiovale.
U ispitanika s Alzheimerovom bolešću, kao i u kontrolnih ispitanika, razina retencije u malom mozgu i hipokampusu je niska, dok pons i centrum semiovale imaju visoku razinu retencije.
In addition a pre-specified multivariate analysis performed on the ITT population demonstrated that vinflunine had a statistically significant treatment effect (p=0.036) on overall survival when prognostic factors (PS, visceral involvement, alkaline phosphatases, haemoglobin, pelvic irradiation) were taken into consideration; hazard ratio 0.77 (95% CI 0.61, 0.98).
Takoñer, prethodno odreñena multivarijantna analiza provedena na populaciji koju se namjeravalo liječiti (ITT) pokazala je da vinflunin ima statistički značajan terapijski učinak (p=0,036) na ukupno preživljenje kad se uzmu u obzir prognostički čimbenici (izvedbeni status, visceralna zahvaćenost, alkalna fosfataza, hemoglobin, zračenje zdjelice); omjer hazarda 0,77 (95%-tni CI 0,61, 0,98).
In addition cases of non-melanoma skin cancer have been observed in patients taking Humira.
Uz to su u bolesnika koji primjenjuju lijek Humira zamijećene i neke vrste nemelanomskih tumora kože.
In addition cases of non-melanoma skin cancer have been observed in patients taking Humira.
Uz to su u bolesnika koji primjenjuju lijek Humira zamijećeni slučajevi nemelanomskog raka kože.
In addition cases of non-melanoma skin cancer have been observed in patients taking Humira.
Uz to su u bolesnika koji uzimaju lijek Humira zamijećene i neke vrste nemelanomskih tumora kože.
In addition eye swelling, dyspnoea and myalgia as adverse reactions have been reported with oral palonosetron but not observed during the development of Akynzeo.
Osim toga, oticanje očiju, dispneja i mijalgija zabilježene su kao nuspojave peroralnog palonozetrona, ali nisu opažene tijekom razvoja lijeka Akynzeo.
In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein.
Osim toga, hidroksikarbamid izaziva trenutačnu inhibiciju sinteze DNA jer djeluje kao inhibitor ribonukleotidne reduktaze, bez utjecaja na sintezu ribonukleinske kiseline ili proteina.
In addition hydroxycarbamide causes an immediate inhibition of DNA synthesis by acting as a ribonucleotide reductase inhibitor, without interfering with the synthesis of ribonucleic acid or protein.
Osim toga, hidroksikarbamid izaziva trenutačnu inhibiciju sinteze DNA jer djeluje kao inhibitorribonukleotidne reduktaze, bez utjecaja na sintezu ribonukleinske kiseline ili proteina.
In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β- carbolines.
Također djelomično poništava smanjenje GABA- i glicin-posredovanih protoka, inducirano cinkom i β-karbolinima.
In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and - carbolines.
Također djelomično poništava smanjenje GABA- i glicin-posredovanih protoka, inducirano cinkom i β-karbolinima.